Avecia sells Pharmaceuticals business unit to Nicholas Piramal India Ltd
The sale includes all Avecia Pharmaceuticals' assets and operations at its principal UK site in Huddersfield, England, a large scale fermentation asset at Billingham, England, a High Potency Substance (HPS) facility at Grangemouth in Scotland and its North American operation - Torcan Chemicals in Aurora, Canada. All 350 Avecia Pharmaceuticals' employees are included in the transaction.
David Killworth, Vice President Avecia Pharmaceuticals said: "I am delighted that we will be joining forces with Nicholas Piramal India Ltd to create a major new force in the custom synthesis business. This transaction brings together the strengths of Indian and Western operations to provide a total lifecycle solution which addresses the changing requirements of the global pharmaceutical and biotechnology sectors".
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.